Article

Aristolochic acid I promoted clonal expansion but did not induce hepatocellular carcinoma in adult rats

Yong-zhen Liu1,2, Heng-lei Lu1,2, Xin-ming Qi2, Guo-zhen Xing2, Xin Wang2, Pan Yu2, Lu Liu2, Fang-fang Yang2, Xiao-lan Ding2, Ze-an Zhang1, Zhong-ping Deng1, Li-kun Gong2,3, Jin Ren2
1 Center for Drug Safety Evaluation and Research, Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
2 Center for Drug Safety Evaluation and Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
3 Zhongshan Institute for Drug Discovery, Institutes of Drug Discovery and Development, CAS, Zhongshan 528400, China
Correspondence to: Zhong-ping Deng: dzp@shutcm.edu.cn, Li-kun Gong: lkgong@cdser.simm.ac.cn, Jin Ren: jren@cdser.simm.ac.cn,
DOI: 10.1038/s41401-021-00622-7
Received: 13 October 2020
Accepted: 6 February 2021
Advance online: 8 March 2021

Abstract

Aristolochic acid I (AAI) is a well-known nephrotoxic carcinogen, which is currently reported to be also associated with hepatocellular carcinoma (HCC). Whether AAI is a direct hepatocarcinogen remains controversial. In this study we investigated the association between AAI exposure and HCC in adult rats using a sensitive rat liver bioassay with several cofactors. Formation of glutathione S-transferase placental form-positive (GST-P+) foci was used as the marker for preneoplastic lesions/clonal expansion. We first conducted a medium-term (8 weeks) study to investigate whether AAI had any tumor-initiating or -promoting activity. Then a long-term (52 weeks) study was conducted to determine whether AAI can directly induce HCC. We showed that oral administration of single dose of AAI (20, 50, or 100 mg/kg) in combination with partial hepatectomy (PH) to stimulate liver proliferation did not induce typical GST-P+ foci in liver. In the 8-week study, only high dose of AAI (10 mg · kg−1 · d−1, 5 days a week for 6 weeks) in combination with PH significantly increased the number and area of GST-P+ foci initiated by diethylnitrosamine (DEN) in liver. Similarly, only high dose of AAI (10 mg· kg−1· d−1, 5 days a week for 52 weeks) in combination with PH significantly increased the number and area of hepatic GST-P+ foci in the 52-week study. No any nodules or HCC were observed in liver of any AAI-treated groups. In contrast, long-term administration of AAI (0.1, 1, 10 mg· kg−1· d−1) time- and dose-dependently caused death due to the occurrence of cancers in the forestomach, intestine, and/or kidney. Besides, AAI-DNA adducts accumulated in the forestomach, kidney, and liver in a time- and dose-dependent manner. Taken together, AAI promotes clonal expansion only in the high-dose group but did not induce any nodules or HCC in liver of adult rats till their deaths caused by cancers developed in the forestomach, intestine, and/or kidney. Findings from our animal studies will pave the way for further large-scale epidemiological investigation of the associations between AA and HCC.
Keywords: aristolochic acid I; glutathione S-transferase placental form-positive foci; clonal expansion; hepatocellular carcinoma; medium-term rat liver bioassay; DNA adducts

Article Options

Download Citation

Cited times in Scopus